Search results
Author(s):
Ken Okumura
Added:
3 years ago
Dr Ken Okumura (Saiseikai Kumamoto Hospital, Kumamoto, JP) discusses the rationale and results behind ELDERCARE-AF, which investigates low dose Edoxaban for elderly Japanese AF patients ineligible for standard anticoagulant therapy.
Questions:
1. What is the rationale for this study?
2. What were the objectives of this study, and its design?
3. What patients were included in the study?
4. What…
View more
Author(s):
Oliver Plunkett
,
Gregory YH Lip
Added:
3 years ago
The introduction of novel oral anticoagulants (NOACs) has widened the treatment options for oral anticoagulation in stroke prevention in non-valvular atrial fibrillation (AF). Guidelines for the management of non-valvular AF have changed to reflect the emerging evidence of their relative safety and efficacy compared with warfarin (see Table 1).1–6
Download original
NOACs are now licensed for…
View more
Author(s):
George D Dangas
Added:
2 years ago
In this short video, Dr George Dangas (Mount Sinai Hospital, New York, NY, US) shares the findings from the ENVISAGE-TAVI AF hot line trial presented at ESC Congress 2021.
ENVISAGE-TAVI AF (Daiichi-Sankyo) compared the safety and efficacy of the DOAC edoxaban with VKAs (warfarin and its analogues) in atrial fibrillation patients with an indication for oral anticoagulation after successful TAVI.
…
View more
Author(s):
Katrina Mountfort
,
A John Camm
,
Gregory YH Lip
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is characterised by rapid and irregular heart rates. It is a lifethreatening condition present in up to 1.5 % of the population and accounts for approximately 15 % of all stroke events.1 While relatively unusual in those under 55 years, its incidence increases substantially with age, particularly between the ages of 65…
View more
Author(s):
Pascal Vranckx
,
Marco Valgimigli
,
Hein Heidbuchel
Added:
3 years ago
Anticoagulation with vitamin K antagonists (VKAs) has been used for the long-term treatment and prevention of thromboembolic diseases and for stroke prevention in atrial fibrillation (AF) for the past half century. Until the last decade, VKAs were the only oral anticoagulant (OAC) agents available, and warfarin remains the most commonly prescribed OAC worldwide.1 Direct oral anticoagulants (DOACs…
View more
Author(s):
Andreas Goette
,
Hein Heidbuchel
Added:
3 years ago
AF is the most common sustained cardiac arrhythmia and poses a significant public health challenge.1 In cases of AF, if sinus rhythm does not spontaneously return, cardioversion may be needed to alleviate symptoms and to improve cardiac performance.2 This may be performed by pharmacological methods, i.e. the administration of antiarrhythmic drugs, which is the preferred strategy in recent-onset…
View more
Author(s):
Paolo Colonna
Added:
4 years ago
Dr Paolo Colonna (Cardiology Department, Policlinico of Bari Hospital, Bari, IT) discusses the EMIT AF/VTE study, which investigates if periprocedural edoxaban management in routine clinical practice is associated with lower bleeding risk.
Filmed on site at EHRA 2019 by Radcliffe Cardiology.
Questions:
1. What is the aim of this study?
2. What is the design of the registry and edoxaban dosing…
View more
Author(s):
Paulus Kirchhof
Added:
7 months ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).
NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,…
View more
Author(s):
Jean-Yves Le Heuzey
Added:
8 years ago
Author(s):
Marco Alings
Added:
3 years ago
Atrial Fibrillation(AF) is the most common cardiac arrhythmia, with the highest prevalence in elderly patients, and is characterised by an irregular heart rhythm that may result in clots in the heart that can spread throughout the circulatory system. It is seen in approximately 2 % of the European adult population and is a significant cause of increasing healthcare costs in developed countries.1…
View more